Basel, Switzerland
T3 Pharmaceuticals AG is a Swiss-based biotechnology startup founded in 2015 with the vision of developing the next generation bacterial cancer therapy. The company aims to address the unmet needs in cancer treatment by providing highly specific and efficient treatments using live bacteria. T3 Pharmaceuticals was established as a spin-off of the University of Basel by Simon Ittig, Christoph Kasper, Marlise Amstutz, and Helmut Kessmann.
The company's proprietary protein delivery technology, based on live bacteria, has diverse applications in research and has been further developed to serve as a novel therapeutic to treat solid tumors. With an unwavering dedication to improving the lives of cancer patients, T3 Pharmaceuticals has garnered significant attention in the investment landscape, receiving a grant investment on 28 April 2023 from Innosuisse.
As the company continues to make strides in the biotechnology industry and demonstrate its potential in revolutionizing cancer treatment, T3 Pharmaceuticals AG stands out as a promising venture that has the potential to make a lasting impact on the lives of cancer patients.
Nectin Therapeutics
